Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022. “NUPLAZID continued to deliver year over year growth in the first quarter of 2022,” said Steve Davis, Chief Executive Officer. “In the near term, we are focused on preparing for the upcoming Advisory Committee meeting in connection with our resubmitted sNDA for pimavanserin in Alzheimer’s disease psychosis. In addition, we have aligned with th
Click here to view original post